PHASE II CLINICAL TRIAL

CDSCO panel gives nod for continuation of phase-II clinical trial of SII's dengue vaccine

"A single dose of dengue vaccine was safe and well tolerated in adults. The vaccine was highly immunogenic with trivalent or tetravalent seroconversion and seropositivity in most of the participants," stated the study results published in Vaccine, a journal by Elsevier, last year in August.